Trillium Therapeutics Inc. is an immuno-oncology company developing therapies for the treatment of cancer. The Company has preclinical programs, targeting the immunoregulatory pathways that tumor cells exploit to evade the host immune system. Trillium's programs include an antibody-like fusion protein that blocks molecules upregulated on malignancies, and a human monoclonal antibody.
96 Skyway Avenue
Toronto, ON M9W 4Y9